At 125x earnings with a Forward P/E of 33.3, the market is clearly discounting a dramatic normalization in profitability, yet the PEG Forward of 0.7 suggests that growth expectations may still outpace valuation compression. A 5.8 Altman Z-Score signals very low bankruptcy risk, and a 3.4 current ratio reinforces short-term balance sheet strength. This is not a distressed biotech gamble; it is a company priced for growth deceleration but not financial stress. The spread between the current P/E and forward multiple implies earnings volatility, yet the balance sheet metrics argue the business is fundamentally stable. The market appears cautious, but not irrational—this is a growth recalibration story rather than a solvency concern.